Osteoboost is the first and only FDA-cleared wearable therapy proven to slow bone loss
More than a decade of independent studies show that vibration activates bone-building cells and improves bone density.
Transforming care for low bone density
Osteopenia affects 54% of postmenopausal women in the U.S. and the majority of fractures occur in patients with osteopenia. Yet treatment options remain limited—guidelines emphasize diet and exercise, while medications are typically reserved for osteoporosis.
Osteoboost, an FDA-cleared Class II device, fills this gap with a safe, effective, and convenient solution.
Osteoboost, an FDA-cleared Class II device, fills this gap with a safe, effective, and convenient solution.
Advancing bone health through a gold-standard pivotal trial
Osteoboost was tested in a randomized, double-blind, sham-controlled trial—the highest standard in research—and showed significant reductions in bone loss.
85% reduction in vertebral bone density loss
Participants who used Osteoboost at least 3 times per week saw an 85% reduction in loss of vertebral bone density after 12 months, compared to the placebo group.
83% reduction in vertebral bone strength loss
Participants who used Osteoboost at least 3 times per week saw an 83% reduction in loss of vertebral bone strength after 12 months, compared to the placebo group.
Simple by design, calibrated for precision
Osteoboost delivers calibrated mechanical stimulation to the lumbar spine and hips, mimicking the benefits of high-impact exercise.
Stand still for automated calibration
Once secured, Osteoboost uses embedded sensors to measure vibration at the iliac crest and automatically adjusts output to deliver a calibrated therapeutic dose (0.1–0.3 g at 20–40 Hz).
How to prescribe Osteoboost
Osteoboost is a Class II prescription device, currently available as self-pay. No prior authorization or in-office setup required.
Step 1
Identify patient with low bone density
Osteoboost is FDA-cleared for postmenopausal women diagnosed with osteopenia (T-score -1.0 to -2.49), providing a safe, effective, and convenient non-drug treatment to help reduce bone loss.
Step 2
Submit prescription to our partner pharmacy
Fax, call, or e-prescribe to HealthWarehouse:
Fax: 1-888-870-2808
Phone: 1-800-748-7001
E-Prescribe: NPI: 1619252160; NCPDP#: 1832674
Fax: 1-888-870-2808
Phone: 1-800-748-7001
E-Prescribe: NPI: 1619252160; NCPDP#: 1832674
Step 3
Instruct patient to order and pay online
Patients must complete their purchase at our website. Both a prescription and order are required for shipment. The device is currently self-pay, and we’re actively working toward reimbursement.
Comprehensive guide for providers
Watch a recorded presentation on the Osteoboost clinical trial and how to integrate it into your practice. Hosted by our clinical team with special guests:
Dr. Laura Bilek, Associate Dean for Research in the College of Allied Health Professions, University of Nebraska Medical Center
Dr. David B. Karpf, Professor of Endocrinology at Stanford, Director of the Osteoporosis and Metabolic Bone Disease Clinic
Dr. Laura Bilek, Associate Dean for Research in the College of Allied Health Professions, University of Nebraska Medical Center
Dr. David B. Karpf, Professor of Endocrinology at Stanford, Director of the Osteoporosis and Metabolic Bone Disease Clinic
Resources for healthcare providers
Explore clinical data, prescribing tools, and support materials—all in one place.
Connect with our team
We’re here to support your practice. Use the form here to request printed materials for your office or schedule an informational session with our team.